Navigation Links
Access Pharmaceuticals Presents New Data at International Symposium Showing Company's Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells
Date:6/26/2008

bination with conventional chemotherapy regimes, as well as compare its efficacy with other anti-angiogenesis drugs, such as Avastin.

The Company is actively seeking potential partners for the further clinical development of Angiolix, a drug which holds great promise as an anti-vascular cancer therapy.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells; Alchemix, a chemotherapeutic agent that combines multiple modes of action to overcome drug resistance. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our ability to close the financing transaction, early results from our clinical trial, Access' plans to continue and initiate clinical trials, the value of its products in the market, its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject t
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
2. A Perfect Storm Threatens Patient Access to Specialty Medical Care
3. AMT Makes Important Advance in the Development of its Gene Therapy for Hemophilia B -Company Accesses Technology to Prevent Immune Response
4. Access Licenses ProLindac(TM) to Jiangsu Aosaikang Pharmaceutical Co., LTD., a Leading Oncology Pharmaceutical Company for Manufacturing, Development and Commercialization in the Greater China Region
5. HistoRx Announces Expanded Access of AQUA(R) Technology to 900+ Researchers at Dana-Farber/Harvard Cancer Center
6. AMT Accesses Technology for Treatment of Duchenne Muscular Dystrophy
7. Access Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. SurgiQuest Announces First Single Port Procedure for Ovary Removal Using AirSeal(TM) Access System
9. Scientists call for more access to biotech crop data
10. Perceptive Informatics Improves Clinical Site Monitoring Access and Flexibility With Portable USB Drive Capability
11. Canadian Centre for DNA Barcoding to Participate in Microchip Biotechnologies Early Access Program for Microchip-Based DNA Sample Preparation and Cycle Sequencing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)NEW YORK, Dec. 2 Nearly 600 medical research executives, scientists, policy makers, and funders today convened to explore novel development approaches and innovative funding strategies at the inaugur
(Date:12/2/2009)TUSTIN, Calif., Dec. 2 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with rel
(Date:12/2/2009)LIBREVILLE, Gabon, December 2 , - "Bolstering Biodiversity in Africa: Everyone,s Problem and Heritage" , Coinciding with the International Year of Biodiversity, 2-3 June 2010 the,Gabonese Rep
(Date:12/2/2009)CAMBRIDGE, Mass., Dec. 2 TechConnect World, an event bringing together the leaders in technology development and product integration in cleantech, nanotech, biotech and MEMS, announced the December 1
Breaking Biology Technology:Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Libreville International Conference 2-3 June 2010 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3
... HEIGHTS, N.J., June 5 Genta,Incorporated (OTC Bul...y,has entered into definitive agreements with inst... Secured Convertible Notes due 2010 totaling in,ag... fees and expenses. The,closing of the first $20 m...out June 6, 2008, subject to the satisfaction of c...
...R, Mich., June 5 Compendia Bioscience today,annou...ment with,GlaxoSmithKline (NYSE: GSK ) for Oncomi...xtension Compendia,s flagship product, Oncomine.,O...s of Oncomine,Professional and Concepts editions b...tary gene expression data in comparison with exist...
...N FRANCISCO, Calif., June 5 Exelixis,Inc. (Nasdaq...ered into an,agreement with Deerfield Management, ...ignificant Exelixis stockholder, to provide Exelix...a flexible credit facility. The,funds can be drawn...iscretion. Exelixis is under no obligation to draw...
Other Biology Technology:Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs 2Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs 3Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs 4GlaxoSmithKline Signs Licensing Agreement With Compendia Bioscience 2Exelixis Receives $150 Million Funding Commitment From Deerfield Management 2Exelixis Receives $150 Million Funding Commitment From Deerfield Management 3Exelixis Receives $150 Million Funding Commitment From Deerfield Management 4Exelixis Receives $150 Million Funding Commitment From Deerfield Management 5
(Date:12/3/2009)The 30-year record low in Antarctic snowmelt that occurred during the 2008-09 austral summer was likely due to concurrent strong positive phases for two main climate drivers, ENSO (El Nio - Southern O
(Date:12/2/2009)PHILADELPHIA Cigarette smoking and alcohol consumption before head and neck cancer diagnosis strongly predicts the patient,s future risk of death, according to published studies. Now, results of a ne
(Date:12/2/2009)PHILADELPHIA Assurance of a cancer-free status did not prompt people participating in a long-term computerized tomography (CT) lung-cancer screening program to pick up their cigarettes again, researc
Breaking Biology News(10 mins):CCNY professor foresees rising Antarctic snowmelt 2Head and neck cancer survivors who use alcohol and cigarettes have increased death risk 2Repeat negative CT scan for lung cancer does not encourage ex-smokers to resume the habit 2Breathing technique can reduce frequency severity of asthma attacks 9990 1Breathing technique can reduce frequency severity of asthma attacks 9990 2Genetic sex determination let ancient species adapt to ocean life 9989 1Genetic sex determination let ancient species adapt to ocean life 9989 2Secretary Shinseki Kicks Off National Sports Clinic 57716 1Secretary Shinseki Kicks Off National Sports Clinic 57716 2
...he German EUREKA Chairmanship 2009/2010! The confe...eral Ministry of Education and Research, will be h...ional Congress Center in Dresden, situated in the ... sights of Dresden., The conference will address ...s for Europe,s global competitiveness and the pote...
...developed countries in the wake of the obesity epi...with the condition. Foot problems are the most com...who are at risk of serious complications such as n...their feet. Both conditions can lead to slow-heali...ted and become gangrenous, can lead to amputation....
...College of Neuropsychopharmacology (ECNP) will be...y. , More than 6,500 clinical and basic scientis...sts and neuroscience researchers from all over the... largest annual high scientific standard congress ... Europe. Renowned experts from 25 countries will p...
Other Biology News:Protective footwear for diabetics at a high-street price 2Protective footwear for diabetics at a high-street price 3
BBMVEC (B840-05) from European Collection of Cell Cultures (ECACC)
Finnpipette Focus Multichannel 8 channel 5-50l from Thermo Scientific
...cal Form: buffered aqueous solution. Cleaves a-...lactose from complex carbohydrates and glycoprotei...nked galactose under conditions where the pH must ... Unit Definition: One unit will hydrolyze 1 mo...
...antibody is specific for human cardiac troponin su...the Ca-binding signals responsible for contraction...e troponin complex in human cells. It also cross-r...SA). Antigen: Highly purified human cardiac tr...
Biology Products: